Large-scale genomic analyses might shed some light on the genomic background of HER2 ultra-low patients in the future, meanwhile, there are very few studies on HER2 ultra-low expression breast cancer, so we need more prospective studies to support our findings. Here, ERBB2 is linked to breast carcinoma.